

Scott J Diede

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/201897/publications.pdf>

Version: 2024-02-01

35
papers

2,941
citations

304743
22
h-index

361022
35
g-index

36
all docs

36
docs citations

36
times ranked

4863
citing authors

#	ARTICLE	IF	CITATIONS
1	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology</i> , The, 2019, 20, 1083-1097.	10.7	611
2	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	1.6	360
3	Telomerase-Mediated Telomere Addition In Vivo Requires DNA Primase and DNA Polymerases α and γ . <i>Cell</i> , 1999, 99, 723-733.	28.9	351
4	The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku. <i>Nature Genetics</i> , 2001, 27, 64-67.	21.4	205
5	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1&2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 121-133.	10.7	204
6	Exonuclease activity is required for sequence addition and Cdc13p loading at a de novo telomere. <i>Current Biology</i> , 2001, 11, 1336-1340.	3.9	136
7	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i> -mutant melanoma. , 2020, 8, e001806.		110
8	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). <i>Translational Oncology</i> , 2019, 12, 828-835.	3.7	90
9	MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. <i>Genes and Development</i> , 2009, 23, 694-707.	5.9	84
10	Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription Factors. <i>Molecular and Cellular Biology</i> , 2013, 33, 773-784.	2.3	62
11	DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 234-239.	7.1	59
12	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
13	Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. <i>Epigenetics</i> , 2012, 7, 400-408.	2.7	56
14	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	2.8	52
15	A duplication at chromosome 11q12.2-11q12.3 is associated with spinocerebellar ataxia type 20. <i>Human Molecular Genetics</i> , 2008, 17, 3847-3853.	2.9	50
16	Spontaneous regression of metastatic cancer: learning from neuroblastoma. <i>Nature Reviews Cancer</i> , 2014, 14, 71-72.	28.4	46
17	Assessment of palindromes as platforms for DNA amplification in breast cancer. <i>Genome Research</i> , 2012, 22, 232-245.	5.5	31
18	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27023.	1.5	31

#	ARTICLE	IF	CITATIONS
19	Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. <i>Future Oncology</i> , 2019, 15, 459-471.	2.4	27
20	Real-world experience with pembrolizumab in patients with advanced melanoma. <i>Medicine (United States)</i> , 2020, 99, 1-11.	1.0	26
21	Expression of neurotrophins and the low-affinity NGF receptor in septal and hippocampal reaggregate cultures: local physiologic effects of NGF synthesized in the septal region. <i>Developmental Brain Research</i> , 1992, 70, 123-133.	1.7	23
22	EEL-1, a Hect E3 ubiquitin ligase, controls asymmetry and persistence of the SKN-1 transcription factor in the early <i>C. elegans</i> embryo. <i>Development (Cambridge)</i> , 2007, 134, 2303-2314.	2.5	23
23	Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles. <i>Nucleic Acids Research</i> , 2013, 41, 9732-9740.	14.5	17
24	Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. <i>Quality of Life Research</i> , 2020, 29, 2651-2660.	3.1	17
25	Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. <i>Epigenetics</i> , 2013, 8, 1254-1260.	2.7	16
26	Impediment of Replication Forks by Long Non-coding RNA Provokes Chromosomal Rearrangements by Error-Prone Restart. <i>Cell Reports</i> , 2017, 21, 2223-2235.	6.4	13
27	Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e218175.	5.9	13
28	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	2.8	13
29	Reduced Dosage of pos-1 Suppresses Mex Mutants and Reveals Complex Interactions Among CCCH Zinc-Finger Proteins During <i>Caenorhabditis elegans</i> Embryogenesis. <i>Genetics</i> , 2006, 174, 1933-1945.	2.9	12
30	TERT hypermethylation: biomarker in paediatric brain tumours. <i>Lancet Oncology</i> , 2013, 14, 447-448.	10.7	7
31	All Things Must End: Telomere Dynamics in Yeast. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2000, 65, 281-296.	1.1	7
32	Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. <i>Journal of Medical Economics</i> , 2020, 23, 132-138.	2.1	6
33	Genome-wide analysis of palindrome formation. <i>Nature Genetics</i> , 2010, 42, 279-279.	21.4	5
34	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2022, 160, 1-11.	2.8	4
35	Factors associated with immunotherapy selection in patients with advanced melanoma. <i>Immunotherapy</i> , 2018, 10, 1361-1369.	2.0	2